Diabetes Res Clin Pract:荟萃分析发现硫辛酸与甲钴胺联合效果优于甲钴胺单药治疗

2013-08-23 MedSci MedSci原创

为了比较每日硫辛酸(300–600mg iv)联合甲钴胺(500–1000mg iv或im)(LA–MC)与单用甲钴胺(MC)对糖尿病周围神经病变(DPN)的有效性和安全性,来自南方医科大学珠江医院季爱民教授及其团队进行了一 项研究(Meta-analysis of methylcobalamin alone and in combination with l

为了比较每日硫辛酸(300–600mg iv)联合甲钴胺(500–1000mg iv或im)(LA–MC)与单用甲钴胺(MC)对糖尿病周围神经病变(DPN)的有效性和安全性,来自南方医科大学珠江医院季爱民教授及其团队进行了一 项研究(Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy),该研究发现LA–MC联合治疗对NCV和神经症状的效果由于MC单药治疗。该研究结果在线发表在2013年8月的 《Diabetes Research and Clinical Practice》上,该杂志影响因子为2.741.该研究中,检索电子数据库中2012年11月1日以前发表的研究,并且一式两份评估研究的质量。使用 随机或固定效应模型分析结果,以风险比(RRs)或平均差(MD)表示。使用I(2)统计量评估异质性。

该研究结果表明,包括17项研究。所有研究的综合数据显示LA–MC联合治疗明显优于MC单药治疗。LA–MC联合治疗的优势表现在神经传导速度 (NCV),正中运动神经传导速度(MNCV)的WMDs为6.89,正中感觉神经传导速度(SNCV)的WMDs为5.24,腓骨MNCV的WMDs为 4.34,以及腓骨SNCV的WMDs为4.53.没有与治疗相关的严重不良事件。

该研究发现,相对于MC治疗,LA–MC治疗2–4周与更好的NCV和神经症状效果有关。然而,需要更大的精心设计的研究来证实这个结论。

原始出处:

Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, Wu P, Deng H, Zhang J, Ji A.Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy.Diabetes Res Clin Pract. 2013 Aug;101(2):99-105.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1681256, encodeId=efbd1681256a0, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Feb 06 03:54:00 CST 2014, time=2014-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901134, encodeId=9dc2190113419, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Jul 09 14:54:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759332, encodeId=4a1f1e5933247, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Sep 27 23:54:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836846, encodeId=4b411836846d6, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sat Mar 01 17:54:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687673, encodeId=ec1a168e67370, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Tue Dec 31 13:54:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636727, encodeId=93d61636e27ef, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Mar 24 23:54:00 CST 2014, time=2014-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514089, encodeId=83b0151408954, content=<a href='/topic/show?id=ae596995efa' target=_blank style='color:#2F92EE;'>#甲钴胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69957, encryptionId=ae596995efa, topicName=甲钴胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443610628065, createdName=124988c7m98暂无昵称, createdTime=Sun Aug 25 00:54:00 CST 2013, time=2013-08-25, status=1, ipAttribution=)]